JP2003508453A5 - - Google Patents

Download PDF

Info

Publication number
JP2003508453A5
JP2003508453A5 JP2001520155A JP2001520155A JP2003508453A5 JP 2003508453 A5 JP2003508453 A5 JP 2003508453A5 JP 2001520155 A JP2001520155 A JP 2001520155A JP 2001520155 A JP2001520155 A JP 2001520155A JP 2003508453 A5 JP2003508453 A5 JP 2003508453A5
Authority
JP
Japan
Prior art keywords
risk
inhibitor
cyclooxygenase
angiotensin
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001520155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003508453A (ja
Filing date
Publication date
Priority claimed from US09/387,028 external-priority patent/US7030152B1/en
Application filed filed Critical
Priority claimed from PCT/US2000/024251 external-priority patent/WO2001015744A1/en
Publication of JP2003508453A publication Critical patent/JP2003508453A/ja
Publication of JP2003508453A5 publication Critical patent/JP2003508453A5/ja
Pending legal-status Critical Current

Links

JP2001520155A 1999-08-31 2000-08-31 アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー Pending JP2003508453A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/387,028 1999-08-31
US09/387,028 US7030152B1 (en) 1997-04-02 1999-08-31 Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
PCT/US2000/024251 WO2001015744A1 (en) 1999-08-31 2000-08-31 Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases

Publications (2)

Publication Number Publication Date
JP2003508453A JP2003508453A (ja) 2003-03-04
JP2003508453A5 true JP2003508453A5 (https=) 2007-11-01

Family

ID=23528141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001520155A Pending JP2003508453A (ja) 1999-08-31 2000-08-31 アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー

Country Status (5)

Country Link
EP (1) EP1212101A1 (https=)
JP (1) JP2003508453A (https=)
AU (1) AU782386C (https=)
CA (1) CA2381926A1 (https=)
WO (1) WO2001015744A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2002012266A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
PT1383786E (pt) 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005515407A (ja) * 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４）
BR0309747A (pt) * 2002-05-03 2005-04-26 Alcon Inc Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
GB0229747D0 (en) 2002-12-20 2003-01-29 Axis Shield Asa Assay
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US20050065184A1 (en) * 2003-08-29 2005-03-24 Aaipharma Inc. Method of reducing the risk of oxidative stress
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005110422A2 (en) * 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
KR20120101064A (ko) 2009-11-13 2012-09-12 비쥐 메디신, 인코포레이티드 심근 경색의 위험 인자 및 예측

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530180T1 (de) * 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
EA199900837A1 (ru) * 1997-04-18 2000-10-30 Дж.Д.Сирл Энд Ко. Способ применения ингибиторов циклооксигеназы-2 для предупреждения сердечно-сосудистых расстройств

Similar Documents

Publication Publication Date Title
JP2003508453A5 (https=)
HUP0100495A3 (en) Use of prostaglandin (pge2)receptor 4 (ep4)selective agonists for producing pharmaceutical compositions suitable for the treatment of acute and chronic renal failure
DZ2936A1 (fr) Composition nouvelle à libération modifiée pour letraitement du diabète.
HK1047693A1 (zh) 治疗全身性焦虑障碍的环苯扎林及其组合物
WO2001068138A3 (en) Intradermal-penetration agents for topical local anesthetic administration
NO20025586D0 (no) Inhibitorer for 11-beta-hydroxy steroid dehydrogenase type 1
GB0001449D0 (en) Compositions
EP1080226A4 (en) COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF OLIGONUCLEOTIDES
IL153497A0 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
WO2001070212A3 (en) Method and composition for preventing or reducing the symptoms of menopause
EE200100293A (et) Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II
WO2004089415A3 (en) COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.
FR2803145B1 (fr) Dispositif d'application d'un retard en ligne
BR9815747A (pt) Composição para liberação de aroma
DK0760238T3 (da) Præparat, der kan indgives perkutant, til behandling af vandladningslidelse
ID27820A (id) APLIKASI-APLIKASI PENGOBATAN POLIPEPTIDA MATURE FLINT (mFLINT) ATAU OPG3, BAGIAN KELOMPOK SUPER RESEPTOR TNF
HK1047036A1 (zh) 用於治疗偏头痛的选择性iglur5，受体拮抗剂
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
WO2004028504A8 (en) Modified release dosage forms
EP1003494A4 (en) (d) -METHADONE, NON-OPIOID ANALGESIC
ZA200102465B (en) A herbal composition and process for the manufacture of such composition for the management of gynaecological disorders.
JP2004500325A5 (https=)